National Urology Group Recruitment 100000 90000 87234 77763 - - PowerPoint PPT Presentation

▶
national urology group recruitment
SMART_READER_LITE
LIVE PREVIEW

National Urology Group Recruitment 100000 90000 87234 77763 - - PowerPoint PPT Presentation

Jan 22, 2023 464 likes •555 views

CRN SWP Business Intelligence Unit Name of report: Cancer Update Q2 2017/2018 31 st October 2017 Release date: Data source(s) used: Portfolio ODP Data cut-off: 30th October 2017 Brief Summary: Summary of recruitment activity to cancer sub

slide-1
SLIDE 1

CRN SWP Business Intelligence Unit

Name of report: Cancer Update Q2 2017/2018 Release date: 31st October 2017 Data source(s) used: Portfolio ODP Data cut-off: 30th October 2017 Brief Summary: Summary of recruitment activity to cancer sub specialty group portfolios nationally and regionally for Q2 of 2017/2018

slide-2
SLIDE 2

Clinical Research Network

Data from Portfolio ODP – cut off 17th July 2017

National Urology Group Recruitment

Data from Portfolio ODP – cut off 30th October 2017

76411 55093 69072 87234 77763 61310 51878 49011 59852 31418 5652 6882 7136 7165 8243 10650 9965 10361 14360 5075

10000 20000 30000 40000 50000 60000 70000 80000 90000 100000 2008/09 2009/10 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 2016/17 2017/18 Cancer Urology

slide-3
SLIDE 3

Clinical Research Network

Data from Portfolio ODP – cut off 17th July 2017

SWP Urology Group Recruitment

Data from Portfolio ODP – cut off 30th October 2017

1200 1960 2012 1823 1549 1797 1559 1612 2038 930 185 254 230 147 224 354 452 490 665 243

500 1000 1500 2000 2500 2008/09 2009/10 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 2016/17 2017/18 Cancer Urology

slide-4
SLIDE 4

Clinical Research Network

Data from Portfolio ODP – cut off 17th July 2017

Urology Group National Perspective

Data from Portfolio ODP – cut off 30th October 2017

200 400 600 800 1000 1200 1400 1600 1800 2000 2015/16 2016/17 2017/18

slide-5
SLIDE 5

Clinical Research Network

Data from Portfolio ODP – cut off 17th July 2017

Urology Group National Perspective

Data from Portfolio ODP – cut off 30th October 2017

CRN 2016/2017 2017/2018 Recruitment Rank

  • Adj. for Pop.

Rank Recruitment Rank

  • Adj. for Pop.

Rank East Midlands 572 13 14 301 8 11 Eastern 941 7 10 287 9 10 Greater Manchester 1845 1 1 523 3 1 Kent, Surrey and Sussex 1538 2 4 605 2 2 North East and North Cumbria 1234 4 3 357 7 5 North Thames 1458 3 9 641 1 6 North West Coast 319 15 15 89 15 15 North West London 843 9 2 128 13 13 South London 1039 6 5 417 5 3 South West Peninsula 665 12 7 243 11 7 Thames Valley and South Midlands 699 11 6 280 10 4 Wessex 800 10 8 237 12 9 West Midlands 847 8 12 366 6 12 West of England 354 14 13 104 14 14 Yorkshire and Humber 1206 5 11 497 4 8

slide-6
SLIDE 6

Clinical Research Network

Data from Portfolio ODP – cut off 17th July 2017

Urology Group SWP Recruitment

Data from Portfolio ODP – cut off 30th October 2017

50 100 150 200 Non-NHS Activity in South West Peninsula NHS South Devon and Torbay CCG NHS Somerset CCG NHS NEW Devon CCG NHS Kernow CCG Yeovil District Hospital NHS Foundation Trust Torbay and South Devon NHS Foundation Trust Taunton and Somerset NHS Foundation Trust Royal Devon and Exeter NHS Foundation Trust Royal Cornwall Hospitals NHS Trust Plymouth Hospitals NHS Trust Northern Devon Healthcare NHS Trust 2015/16 2016/17 2017/18

slide-7
SLIDE 7

Clinical Research Network

Data from Portfolio ODP – cut off 17th July 2017

Key Trials

  • Prostate

–Add Aspirin (any prostate RT pt or post prostatectomy pt) –PIVOTAL BOOST (HDR vs IMRT boost to prostate tumour and/

  • r hypofactionated pelvic RT)

–STAMPEDE

  • Bladder

–RAIDER (adaptive bladder radiotherapy +/- tumour boost) –ATLANTIS (all sites to consider opening; STAMPEDE like maintenance study following response after first line platinum based palliative chemotherapy)

  • Renal

–RAMPART (adjuvant single or combination immunotherapy post nephrectomy in patients with intermediate or high risk RCC).

7

slide-8
SLIDE 8

Clinical Research Network

Data from Portfolio ODP – cut off 17th July 2017

The Future

  • Continue to refer to Urology portfolio maps in MDT to facilitate

network referrals

  • https://sites.google.com/a/nihr.ac.uk/crn-south-west-

peninsula/business-intelligence-unit-1/cancer-portfolio- maps/urology-portfolio

  • Immunotherapy studies being considered within the UK for high risk

non-muscle invasive bladder cancers –Important to have this within the network –Need to consider how this group of patients will be managed, as will need to be seen by oncology

  • All MDT members invited to the Network bladder cancer study day

26/01/2017 Exeter ‘Embracing a multidisciplinary and evidence based approach’

8